BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29271183)

  • 1. Subclassification and Detection of New Markers for the Discrimination of Primary Liver Tumors by Gene Expression Analysis Using Oligonucleotide Arrays.
    Hass HG; Vogel U; Scheurlen M; Jobst J
    Gut Liver; 2018 May; 12(3):306-315. PubMed ID: 29271183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.
    Likhitrattanapisal S; Tipanee J; Janvilisri T
    Tumour Biol; 2016 Sep; 37(9):12755-12766. PubMed ID: 27448818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC (CHC) with each other based on microarray dataset.
    Wang L
    Tumour Biol; 2013 Jun; 34(3):1679-84. PubMed ID: 23532688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis.
    Hass HG; Nehls O; Jobst J; Frilling A; Vogel U; Kaiser S
    World J Gastroenterol; 2008 Apr; 14(16):2501-10. PubMed ID: 18442196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panel of potential lncRNA biomarkers can distinguish various types of liver malignant and benign tumors.
    Burenina OY; Lazarevich NL; Kustova IF; Shavochkina DA; Moroz EA; Kudashkin NE; Patyutko YI; Metelin AV; Kim EF; Skvortsov DA; Zatsepin TS; Rubtsova MP; Dontsova OA
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):49-59. PubMed ID: 32918630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of immunohistochemical markers for differential diagnosis of hepatocelluar carcinoma and cholangiocarcinoma.
    Ryu HS; Lee K; Shin E; Kim SH; Jing J; Jung HY; Lee H; Jang JJ
    Tumori; 2012; 98(4):478-84. PubMed ID: 23052165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Gene Expression Analysis for Discrimination of Primary and Secondary Adenocarcinoma of the Liver.
    Hass HG; Vogel U; Scheurlen M; Jobst J
    Oncology; 2018; 95(4):211-219. PubMed ID: 29920486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
    Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
    J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
    Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY
    Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma.
    Liu B; Hervé J; Bioulac-Sage P; Valogne Y; Roux J; Yilmaz F; Boisgard R; Guettier C; Calès P; Tavitian B; Samuel D; Clerc J; Bréchot C; Faivre J
    Gastroenterology; 2007 Apr; 132(4):1495-503. PubMed ID: 17408651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers of intrahepatic cholangiocarcinoma: diagnosis and response to therapy.
    Brown ZJ; Hewitt DB; Pawlik TM
    Front Biosci (Landmark Ed); 2022 Mar; 27(3):85. PubMed ID: 35345317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma.
    Xiao SY; Wang HL; Hart J; Fleming D; Beard MR
    Am J Pathol; 2001 Oct; 159(4):1415-21. PubMed ID: 11583969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
    Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N
    J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing.
    Jeon J; Maeng LS; Bae YJ; Lee EJ; Yoon YC; Yoon N
    Cancer Genomics Proteomics; 2018; 15(4):291-298. PubMed ID: 29976634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
    Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
    Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined hepatocellular-cholangiocarcinoma with stem cell features, ductal plate malformation subtype: a case report and proposal of a new subtype.
    Terada T
    Int J Clin Exp Pathol; 2013; 6(4):737-48. PubMed ID: 23573322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma.
    Nishino R; Honda M; Yamashita T; Takatori H; Minato H; Zen Y; Sasaki M; Takamura H; Horimoto K; Ohta T; Nakanuma Y; Kaneko S
    J Hepatol; 2008 Aug; 49(2):207-16. PubMed ID: 18490072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
    Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
    Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.